CN111454216B - Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof - Google Patents
Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof Download PDFInfo
- Publication number
- CN111454216B CN111454216B CN202010399868.9A CN202010399868A CN111454216B CN 111454216 B CN111454216 B CN 111454216B CN 202010399868 A CN202010399868 A CN 202010399868A CN 111454216 B CN111454216 B CN 111454216B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- benzyl
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a preparation method of HMG-CoA reductase inhibitor and intermediate thereof, wherein a new compound with Evans prosthetic group structure is introduced as a key intermediate in the synthetic route, JULIA alkene is adopted to improve the selectivity of E/Z, the conditions are mild when the prosthetic group is removed, the isomerization and impurity elimination can be avoided, the synthetic route is simple, the key intermediates (the compound of formula 5 and the compound of formula 6) are solid, the product purification and the material scientific putting reaction are convenient, and thus the high-purity product is obtained.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to a preparation method of an HMG-CoA reductase inhibitor and an intermediate thereof.
Background
Rosuvastatin (Rosuvastatin) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase (HMG-CoA reductase), and can be used for the treatment of hypercholesterolemia and mixed dyslipidemia, and can reduce elevated concentrations of low density cholesterol, total cholesterol, triglycerides and apoprotein B, while elevating the concentration of high density cholesterol; can be used for the comprehensive treatment of primary hypercholesterolemia, mixed lipodystrophy and homozygous familial hypercholesterolemia, and is called super statin.
Rosuvastatin is administered as its calcium salt in therapy and is a single enantiomer, marketed in several countries and regions of the united states, japan, europe, china, etc., with the chemical name bis- [ E-7- [4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] -pyrimidin-5-yl ] (3R,5S) -3, 5-dihydroxyhept-6-enoic acid ] calcium salt (2: 1) and the chemical structure is as follows:
at present, a plurality of synthetic routes of rosuvastatin calcium are reported, but most of the synthetic routes are developed for avoiding the technical protection of original manufacturers.
For example: EP0521471a1 reports the following synthetic method:
WO0049014a1 discloses the following synthetic method:
the multi-step synthesis intermediate of the synthesis route disclosed above is oily, and most of the synthesis processes adopt WITIG reaction, and the Z/E selectivity is poorly controlled.
CN201910190264 discloses the following synthesis method:
the side chain synthesized by the above-mentioned circuit is oxidized from olefin to aldehyde, so that the yield is not high, and the product purity is not high easily due to the use of an oxidation system.
In general, the technical problems of the current synthetic routes are: the synthetic route is complex, the quality control and purification of oily intermediates are difficult, the E/Z selectivity needs to be improved, and higher product purity is difficult to obtain.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a preparation method of an HMG-CoA reductase inhibitor and an intermediate thereof. A new compound with an Evans prosthetic group structure is introduced into the synthetic route as a key intermediate, so that the intermediate involved in the whole synthetic route is solid and convenient to purify, the provided E/Z selectivity is improved, and the product purity is high.
In order to solve the technical problems, the invention provides the following technical scheme:
in one aspect, the present invention provides a method for preparing an HMG-CoA reductase inhibitor, which comprises converting a compound of formula 6 into a compound of formula 8:
< formula 8>
< formula 6>
Wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
Further, the compound of formula 6 is oxidized under the action of alkali, and after the reaction is finished, the compound is regulated by acid, separated and reacted with a calcium reagent to prepare the compound of formula 8. Further, the reaction is carried out in a solvent selected from the group consisting of THF, dichloromethane, water, C1-C10 alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), dichloromethane, acetonitrile, and mixtures thereof; preferred are THF/water mixtures in a volume ratio of 1:1,1:2,1:3,2:1,3:1, etc.
Still further, the base includes sodium hydroxide, lithium hydroxide, potassium carbonate, potassium phosphate, potassium hydrogen phosphate, ammonia water, and the like.
Furthermore, the oxidizing agent used in the oxidation reaction comprises hydrogen peroxide, sodium peroxide, Fenton reagent and the like.
Still further, the acid is hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, formic acid, sulfonic acid, and mixtures thereof; preferably an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid. Furthermore, the mass percentage concentration of the acid is 1-5%, and preferably 3%.
Further, the separation process is as follows: and adding an ether solvent into the mixture after acid adjustment for extraction and separation, and directly reacting the solvent layer with a calcium reagent after concentration. Ether type solvents include MTBE, THF, CPME and the like.
Further, the separation process is as follows: MTBE (methyl tert-butyl ether) is added into the mixture after the pH value is adjusted to 9-10 by acid for extraction and separation, and an MTBE layer is directly used for reaction with calcium acetate after being concentrated.
In another aspect, the invention provides a compound of formula 6:
< formula 6>
Wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
In yet another aspect, the present invention provides a method for preparing a compound of formula 6, comprising converting a compound of formula 5 into a compound of formula 6:
< formula 5>
Wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
Further, the compound of formula 5 is hydrolyzed by acid to prepare the compound of formula 6. Still further, the acid is hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, formic acid, sulfonic acid, and mixtures thereof; preferably an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid; furthermore, the mass percentage concentration of the acid is 1-10%, preferably 1-5%, preferably 5%. Further, the reaction is carried out in a solvent selected from the group consisting of THF, dichloromethane, water, C1-10Alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), dichloromethane, acetonitrile, and mixtures thereof.
In another aspect, the invention provides a compound of formula 5:
< formula 5>
Wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
In yet another aspect, the present invention provides a method for preparing a compound of formula 5, comprising reacting a compound of formula 4 with a compound of formula Z9 to prepare a compound of formula 5:
wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
Further, the compound of the formula 4 and the compound of the formula Z9 react under the action of alkali, and the compound of the formula 5 is prepared after quenching by ammonium salt.
Further, the base is a potassium alkoxide/alcohol reagent, a sodium alkoxide/alcohol reagent, or the like; the alcohol is C1-4Alcohols of (a), for example: methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, etc. The ammonium salt is ammonium chloride and the like. The reaction is carried out in a reagent selected from THF, dichloromethane, water, C1-C10 alcohol (such as methanol, ethanol, isopropanol, butanol, etc.)) Dichloromethane, acetonitrile and mixtures thereof. The base is mixed with a solvent and then added dropwise before being added to the reaction system.
In another aspect, the present invention provides a compound of formula 4:
< formula 4>
Wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
In still another aspect, the present invention provides a method for preparing a compound of formula 4, which comprises reacting a compound of formula 3, DCC, R-oxazolidinone and DMAP to obtain a compound of formula 4:
wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group.
Further, the reaction is carried out in a solvent, which is water, a C1-C10 alcohol (such as methanol, ethanol, isopropanol, butanol, etc.), dichloromethane, tetrahydrofuran, acetonitrile, and mixtures thereof. The reaction is carried out at room temperature. The molar ratio of the compound of formula 3 to DCC to R-oxazolidinone was 1:1: 2. The DMAP was used in an amount of 10% wt of the total reactants.
On one hand, the invention provides a preparation method of rosuvastatin calcium, which comprises the following specific steps:
1) preparation of the Compound of formula 2
PMTA、Na2CO3And the compound of the formula 1 are heated to react to obtain a compound of a formula 2;
2) preparation of the Compound of formula 3
A compound of formula 2, amine heptamolybdate and H2O2Stirring and reacting to obtain a compound shown in a formula 3;
3) preparation of the Compound of formula 4
Reacting the compound of the formula 3, R-oxazolidinone, DCC and DMAP to obtain a compound of a formula 4; wherein R is H, alkyl, phenyl, benzyl, etc.; further, R is H, C1-12Alkyl, phenyl, benzyl, etc.; further, R is H, C1-6Alkyl, phenyl, benzyl, etc.; further, R is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, phenyl, benzyl, etc. R may be further substituted with any group;
4) preparation of Compounds of formula 5
Dripping t-BuOK THF/t-BuOH solution into the mixed solution of the compound of the formula 4 and the compound of the formula Z-9, continuing the reaction after the addition is finished, and dripping saturated ammonium chloride after the reaction is finished to quench to obtain a compound of the formula 5;
5) preparation of the Compound of formula 6
Dissolving the compound shown in the formula 5 in THF, dropwise adding acid, and stirring to complete hydrolysis to obtain a compound shown in the formula 6;
6) preparation of the Compound of formula 7
Compounds of formula 6 with LiOH and H2O2After the stirring reaction is completed, the mixture obtained by post-treatment is directly used for the next reaction;
7) preparation of the Compound of formula 8
Adding purified water into the mixture obtained in the last step for dissolving, dropwise adding a calcium acetate solution, stirring for reacting, centrifuging, leaching purified water, and spin-drying to obtain a rosuvastatin calcium wet refined product;
further, in step 1), the PMTA and Na2CO3And the compound of formula 1 in a molar ratio of 1:1 to 1.5: 1; preferably 1:1.2: 1; the temperature of the heating reaction is 90 ℃; the reaction is carried out in a solvent, wherein the solvent is water and C1-10Alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), DMF, tetrahydrofuran, acetonitrile, and mixtures thereof.
Further, in the step 2), the reaction is carried out in a solvent at room temperature, wherein the solvent is water and C1-10Alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), DMF, tetrahydrofuran, acetonitrile, and mixtures thereof. In the invention, the room temperature is 15-35 ℃, for example: 25 ℃,18 ℃ and the like.
Further, in the step 3), the molar ratio of the compound of the formula 3, R-oxazolidinone and DCC is 1:1: 2; the reaction is carried out in a solvent at room temperature, wherein the solvent is water and C1-10Alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), DMF, dichloromethane, tetrahydrofuran, acetonitrile, and mixtures thereof.
Further, in the step 4), the reaction is carried out in a solvent at room temperature, wherein the solvent is water and C1-10Alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), DMF, dichloromethane, tetrahydrofuran, acetonitrile, and mixtures thereof.
Further, in step 5), the reaction is carried out at room temperature, and further, the acid is hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, formic acid, sulfonic acid and a mixture thereof; preferably an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid; furthermore, the mass percentage concentration of the acid is 1-10%, preferably 1-5%, preferably 5%.
Further, in step 6), the compound of formula 6 is dissolved in THF/H2In O, with LiOH and H2O2After the stirring reaction is completed, stirring the mixture,quenching hydrogen peroxide by saturated sodium bisulfite, distilling under reduced pressure to remove THF, adding purified water, adjusting pH to 9-10 by 3% HCl, adding MTBE into the reactor, stirring, separating liquid, washing the water phase once by MTBE, distilling under reduced pressure at 40 +/-5 ℃ until the MTBE is less than or equal to 5000ppm, and directly using the obtained mixture in the next reaction.
Advantageous effects
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a preparation method of HMG-CoA reductase inhibitor and intermediate thereof. A new compound with an Evans prosthetic group structure is introduced into a synthesis route as a key intermediate, JULIA alkene is adopted, the selectivity of E/Z is improved, the conditions are mild when the prosthetic group is removed, isomerization and impurity elimination can be avoided, the synthesis route is simple, the key intermediates (the compounds shown in the formulas 5 and 6) are solid, the product purification and the material scientific putting reaction are facilitated, and therefore a high-purity product is obtained.
At present, JULIA alkene-forming reaction mostly needs ultralow temperature and expensive strong base, materials used in the synthesis route are all reagents with low price or easy obtaining in the conventional way, and the alkene-forming reaction is carried out at relatively high temperature, so that the operation is simple, the cost is low, and the pollution is small.
In the process of synthesizing rosuvastatin calcium, the harsh conditions of low-temperature reaction (the lowest temperature of the invention is only-40 ℃) are avoided, most of the intermediate synthesis process can be carried out at room temperature, the industrial production is more favorably realized, and the yield and the purity of the synthesized product are improved.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments, but it should not be construed that the scope of the subject matter of the present invention is limited to the examples.
The process equipment or devices not specifically noted in the following examples are conventional in the art; all reagents are commercially available.
Example 1
Preparation of Compound 2
PMTA (3.2g, 1) at room temperature8.0mmol) was dissolved in DMF (20mL), Na was added sequentially2CO3(2.2g,21.6mmol) and compound 1(4g,18mmol) were heated to 90 ℃ for 24h and examined by LC-Ms.
After addition of 10mL of water, pH 5-6 was adjusted with 10% HCl, extracted with dichloromethane (40mL × 2), the organic phases were combined, dried with water (10mL × 2), and concentrated in vacuo at 40 ℃ to give an oil which was used in the next step.
LC-Ms：[M+H]＝365.20。
Preparation of Compound 3
To the oil from the previous step, iPrOH (20mL) was added at room temperature followed by heptamolybdate (1.1g) and H2O2(20mL), after the addition, the reaction was continued for 18h at 25 ℃ and the Lc-Ms detected that the reaction was complete.
Adding 60mL of dichloromethane for extraction, quenching hydrogen peroxide by using saturated sodium bisulfite, separating, washing an organic phase by using 20mL of water, drying, and carrying out vacuum concentration at 40 ℃ to obtain 4g of a product, wherein the total yield of the two steps is 56%.
LC-Ms：[M+H]＝397.05
Preparation of Compound 4
30mL of dichloromethane were added to Compound 3(4g,10.1mmol) at room temperature, followed by benzyl oxazolidinone (1.78g,10.1mmol), DCC (4.16g,20.2mmol) and DMAP (0.4g, 10% wt) and stirring continued for 18 h. Concentration in vacuo and purification by column chromatography (EA/PE ═ 1:2) gave 4.9g of product in 87% yield. LC-Ms: [ M + Na ] ═ 578.15
Preparation of Compound 5
At room temperature, the compound 4(4.0g, 7.20mmol) and Z-9(2.53g, 7.20mmol) are dissolved in 40mL of THF, the temperature is reduced to-40 ℃, a THF/t-BuOH solution of t-BuOK (1.1eq) is added dropwise, the reaction is continued for 4h after the addition, 10mL of saturated ammonium chloride is added dropwise for quenching, the temperature is raised to room temperature, the solution is stirred and separated, and the oily substance is obtained after vacuum concentration at 40 ℃. The oil was purified by column chromatography (EA/PE ═ 1:4) to give 3.8g of a white solid (R ═ benzyl) in 78% yield.
HNMR(CDCl3，400M)：δ(ppm)：1.30(8H,m),1.41(3H,s),1.55(3H,s),2.68(1H,dd),3.05(1H,dd),3.20(1H,dd),3.30(1H,dd),3.41(1H,m),3.51(3H,s),3.60(3H,s),4.20(2H,m),4.51(2H,m),4.71(1H,m),5.52(1H,dd),6.55(1H,d),7.11(2H,m),7.25(5H,m),7.68(2H,m)
Preparation of Compound 6
Compound 5(3.5g, 5.15mmol) was dissolved in THF (35mL) at rt, 5% dilute hydrochloric acid was added dropwise to pH 2-4, stirred for 2h, and hydrolysis was complete. EA (50mL) was added and extracted once, and washed with saturated brine (15mL), the layers were separated and the organic phase was concentrated in vacuo to give 3.1g of a white solid (R ═ benzyl) in 95% yield.
LC-Ms：[M+H]＝641.15
HNMR(CDCl3，400M)：δ(ppm)：1.35(2H,m),1.45(3H,s),1.60(3H,s),2.70(1H,dd),3.10(1H,dd),3.25(1H,dd),3.35(1H,dd),3.42(1H,m),3.52(3H,s),3.62(3H,s),4.21(2H,m),4.52(2H,m),4.71(1H,m),5.52(1H,dd),6.60(1H,d),7.15(2H,m),7.28(5H,m),7.70(2H,m)
Preparation of Compound 7
Compound 6(1.1g,1.7mmol) was dissolved in THF/H at 0 deg.C2To O, LiOH (0.5g,20.8mmol) and H were added in this order2O2(2mL), after the reaction is completely stirred, quenching hydrogen peroxide by saturated sodium bisulfite, removing THF by reduced pressure distillation, adding purified water (3mL/g), adjusting the pH to 9-10 by 3% HCl, adding MTBE (8mL/g) into the reactor, stirring for 30min, separating liquid, washing the aqueous phase once again by MTBE (8mL/g), and reducing the pressure distillation at 40 +/-5 ℃ until the MTBE is less than or equal to 5000ppm, wherein the obtained aqueous liquid is directly used for the next reaction
Preparation of API
Adding purified water (20mL) into the water solution obtained in the last step, controlling the temperature to 25 ℃, dropwise adding a calcium acetate (12.3g) solution, stirring for 30min after dropwise adding, performing suction filtration, and washing with purified water to obtain a rosuvastatin calcium wet refined product. Vacuum drying at 50 + -5 deg.C to water content of less than or equal to 3.0% to obtain 0.61g white solid with yield of 71% and purity of 99.9%.
Example 2
Preparation of Compound 2
PMTA (12.0g,67.5mmol) was dissolved in DMF (50mL) at room temperature, followed by the addition of Na2CO3(7.1g,67.5mmol) and Compound 1(10g,45.0mmol) were heated to 90 ℃ and reacted for 24h to completion.
After addition of 25mL of water, pH 5-6 was adjusted with 10% HCl, extracted with dichloromethane (100mL × 2), the organic phases were combined, dried with water (25mL × 2), and concentrated in vacuo at 40 ℃ to give an oil which was used in the next step.
Preparation of Compound 3
To the oil from the previous step, iPrOH (50mL) was added at room temperature followed by heptamolybdate (2.7g) and H2O2(50mL) after the addition, the reaction was stirred at 25 ℃ for 18h to complete.
After 150mL of dichloromethane is added for extraction and liquid separation, saturated sodium bisulfite is used for quenching hydrogen peroxide for liquid separation, 50mL of water is used for washing an organic phase, drying is carried out, vacuum concentration is carried out at 40 ℃, 12.0g of a product is obtained, and the total yield of two steps is 68%.
Preparation of Compound 4
80mL of dichloromethane was added to Compound 3(12.0g,30.4mmol) at room temperature, followed by oxazolidinone (2.6g,30.4mmol), DCC (12.5g,60.8mmol) and DMAP (1.2g, 10% wt) and stirring continued for 20 h. Concentration in vacuo and purification by column chromatography (EA/PE ═ 1:2) gave 11.5g of product in 81% yield. Lc-Ms: [ M + Na ] ═ 488.12
Preparation of Compound 5
At room temperature, the compound 4(10.0g, 21.5mmol) and Z-9(7.0g, 20.0mmol) are dissolved in 50mL THF, the temperature is reduced to-40 ℃, a THF/t-BuOH solution of t-BuOK (1.1eq) is added dropwise, the reaction is continued for 4h after the addition, 5mL saturated ammonium chloride is added dropwise for quenching, the temperature is raised to room temperature, the solution is stirred and separated, and the oily substance is obtained after vacuum concentration at 40 ℃. The oil was purified by column chromatography (EA/PE ═ 1:4) to give 10.0g of a white solid (R ═ H) in 85% yield.
Lc-Ms:[M+H]＝591.22
HNMR(CDCl3，400M)：δ(ppm)：1.31(8H,m),1.42(3H,s),1.57(3H,s),2.70(1H,dd),3.10(1H,dd),3.41(1H,m),3.52(3H,s),3.60(3H,s),4.05(2H,t),4.21(2H,m),4.55(2H,t),5.52(1H,dd),6.55(1H,d),7.11(2H,m),7.68(2H,m)
Preparation of Compound 6
Compound 5(8.0g, 13.5mmol) was dissolved in THF (100mL) at room temperature, 5% dilute hydrochloric acid was added dropwise to pH 2-4, stirred for 2h, and hydrolysis was complete. EA (100mL) was added and extracted once, and washed with saturated brine (50mL), separated, and the organic phase was concentrated in vacuo to give 7.0g of a white solid (R ═ H) with a yield of 94%.
Lc-Ms:[M+H]＝551.20
HNMR(CDCl3，400M)：δ(ppm)：1.36(2H,m),1.45(3H,s),1.61(3H,s),2.70(1H,dd),3.10(1H,dd),3.41(1H,m),3.52(3H,s),3.60(3H,s),4.07(2H,t),4.22(2H,m),4.57(2H,t),5.53(1H,dd),6.60(1H,d),7.16(2H,m),7.71(2H,m)
Preparation of Compound 7
Compound 6(7.0g, 12.7mmol) was dissolved in THF/H at 0 deg.C2To O, LiOH (3.0g, 12.7mmol) and H were added in this order2O2(14mL), after the reaction is completely stirred, quenching hydrogen peroxide by saturated sodium bisulfite, removing THF by reduced pressure distillation, adding purified water (3mL/g), adjusting the pH to 9-10 by 3% HCl, adding MTBE (8mL/g) into the reactor, stirring for 30min, separating liquid, washing the aqueous phase once again by MTBE (8mL/g), and reducing the pressure distillation at 40 +/-5 ℃ until the MTBE is less than or equal to 5000ppm, wherein the obtained aqueous liquid is directly used for the next reaction
Preparation of API
Adding purified water (140mL) into the water solution obtained in the last step, controlling the temperature to 25 ℃, dropwise adding a calcium acetate (70g) solution, stirring for 30min after dropwise adding, carrying out suction filtration, and washing with purified water to obtain a rosuvastatin calcium wet refined product. Vacuum drying at 50 + -5 deg.C to water content of less than or equal to 3.0% to obtain 4.7g white solid with yield of 75% in two steps and purity of 99.9%.
It will be understood that the above embodiments are merely exemplary embodiments taken to illustrate the principles of the present invention, which is not limited thereto. It will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention, and these changes and modifications are also considered to be included in the scope of the invention.
Claims (4)
1. A process for the preparation of an HMG-CoA reductase inhibitor, comprising:
a) hydrolyzing the compound of formula 5 with acid to obtain the compound of formula 6
< formula 5>
Wherein R is H, alkyl, phenyl, benzyl;
b) converting the compound of formula 6 to a compound of formula 8:
< formula 8>
< formula 6>
Wherein R is H, alkyl, phenyl, benzyl;
the compound of the formula 6 is subjected to oxidation reaction under the action of alkali, and after the reaction is finished, the compound is subjected to acid regulation and separation and then reacts with a calcium reagent to prepare a compound of a formula 8; the separation process is as follows: and adding an ether solvent into the mixture after acid adjustment for extraction and separation, and directly reacting the solvent layer with a calcium reagent after concentration.
2. A compound of formula 5 having the formula:
< formula 5>
Wherein R is H, alkyl, phenyl, benzyl.
3. A method for preparing a compound of formula 5, wherein the compound of formula 4 and the compound of formula Z9 are reacted under the action of a base, and the compound of formula 5 is prepared after quenching by ammonium salt:
wherein R is H, alkyl, phenyl, benzyl.
4. The method according to claim 3, which comprises reacting the compound of formula 3, DCC, R-oxazolidinone and DMAP to obtain a compound of formula 4:
wherein R is H, alkyl, phenyl, benzyl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010399868.9A CN111454216B (en) | 2019-10-21 | 2019-10-21 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910997404.5A CN110642790B (en) | 2019-10-21 | 2019-10-21 | Preparation method of rosuvastatin calcium and intermediate thereof |
| CN202010399868.9A CN111454216B (en) | 2019-10-21 | 2019-10-21 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910997404.5A Division CN110642790B (en) | 2019-10-21 | 2019-10-21 | Preparation method of rosuvastatin calcium and intermediate thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111454216A CN111454216A (en) | 2020-07-28 |
| CN111454216B true CN111454216B (en) | 2021-06-29 |
Family
ID=68994341
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010498843.4A Pending CN111518034A (en) | 2019-10-21 | 2019-10-21 | Preparation method of statin compound and intermediate thereof |
| CN201910997404.5A Active CN110642790B (en) | 2019-10-21 | 2019-10-21 | Preparation method of rosuvastatin calcium and intermediate thereof |
| CN202010399868.9A Active CN111454216B (en) | 2019-10-21 | 2019-10-21 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010498843.4A Pending CN111518034A (en) | 2019-10-21 | 2019-10-21 | Preparation method of statin compound and intermediate thereof |
| CN201910997404.5A Active CN110642790B (en) | 2019-10-21 | 2019-10-21 | Preparation method of rosuvastatin calcium and intermediate thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN111518034A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518034A (en) * | 2019-10-21 | 2020-08-11 | 山东理工职业学院 | Preparation method of statin compound and intermediate thereof |
| CN112028881B (en) * | 2020-09-02 | 2023-08-15 | 能特科技有限公司 | Synthesis method of rosuvastatin calcium higher intermediate R-1 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| TWI292396B (en) * | 2001-03-19 | 2008-01-11 | Astrazeneca Uk Ltd | Pyrimidine deriv atives |
| JP2004536813A (en) * | 2001-06-06 | 2004-12-09 | ブリストル−マイヤーズ スクイブ カンパニー | Chiral diol sulfone and dihydroxy acid HMGCoA reductase inhibitors |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EP1869005A1 (en) * | 2005-04-04 | 2007-12-26 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
| WO2008044243A2 (en) * | 2006-10-09 | 2008-04-17 | Manne Satyanarayana Reddy | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| WO2008072078A1 (en) * | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
| US20090054450A1 (en) * | 2007-06-19 | 2009-02-26 | Ironwood Pharmaceuticals, Inc. | Compositions and methods of use for treating or preventing lipid related disorders |
| EP2752407B1 (en) * | 2009-01-14 | 2015-09-23 | Krka Tovarna Zdravil, D.D., Novo Mesto | Crystalline rosuvastatin calcium trihydrate |
| EP2526099B1 (en) * | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| WO2011104725A2 (en) * | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| CN102219780B (en) * | 2010-04-14 | 2014-08-06 | 上海京新生物医药有限公司 | Method for preparing (3R, 5S, E)-7-{2-(N-methylsulphonylamino) -4-(4-fluorophenyl)-6-isopropyl-pyrimidine-5-yl}-2,2-dimethyl-3,5-dioxane-6-heptenoic acid |
| KR101292238B1 (en) * | 2010-07-01 | 2013-07-31 | 주식회사유한양행 | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
| HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
| US9126975B2 (en) * | 2011-01-18 | 2015-09-08 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of statins in the presence of base |
| CN102358747B (en) * | 2011-08-30 | 2012-09-19 | 浙江宏元药业有限公司 | Rosuvastatin calcium intermediate and method for preparing rosuvastatin calcium intermediate and rosuvastatin calcium |
| KR20140017207A (en) * | 2012-07-31 | 2014-02-11 | 미래파인켐 주식회사 | Rosuvastatin isopropyl amine salt, the preparation method thereof and the preparation method of rosuvastatin hemicalcium salt using the same |
| CN105132477A (en) * | 2015-08-06 | 2015-12-09 | 苏州汉酶生物技术有限公司 | Preparation method of (4R-cis)-6-chloromethyl-2, 2-dimethyl-1, 3-dioxane-4-acetic acid isopropyl ester |
| CN108047140A (en) * | 2018-01-18 | 2018-05-18 | 山东理工职业学院 | The preparation method of HMG-CoA reductase inhibitor and its intermediate |
| CN111518034A (en) * | 2019-10-21 | 2020-08-11 | 山东理工职业学院 | Preparation method of statin compound and intermediate thereof |
-
2019
- 2019-10-21 CN CN202010498843.4A patent/CN111518034A/en active Pending
- 2019-10-21 CN CN201910997404.5A patent/CN110642790B/en active Active
- 2019-10-21 CN CN202010399868.9A patent/CN111454216B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111454216A (en) | 2020-07-28 |
| CN111518034A (en) | 2020-08-11 |
| CN110642790A (en) | 2020-01-03 |
| CN110642790B (en) | 2021-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106928227B (en) | Synthetic method of entecavir and intermediate compound thereof | |
| CN111454216B (en) | Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof | |
| US8822716B2 (en) | Intermediate of cilastatin and preparation method thereof | |
| CN114539048B (en) | Carlong anhydride intermediate and preparation method of Carlong anhydride | |
| JPS6046104B2 (en) | Method for producing butene derivatives | |
| CN114702425A (en) | Preparation method of (S) -2-amino- (S) -3- [ pyrrolidone-2' ] alanine derivative and intermediate | |
| CN113121549B (en) | Method for stereoselectively synthesizing chiral lactone, chiral compound and application thereof | |
| JP5463051B2 (en) | Method for producing 1,4-dihydropyridine derivative | |
| JP3855570B2 (en) | Process for producing 4-acetyltetrahydropyran | |
| JP2003192626A (en) | Method for producing 2-adamantanone | |
| CN111072543B (en) | Preparation method and application of (3R,4S) -4-ethylpyrrolidine-3-carboxylic acid compound | |
| CN108047140A (en) | The preparation method of HMG-CoA reductase inhibitor and its intermediate | |
| JP2004131399A (en) | Method for producing cis-hexahydroisoindoline | |
| JP4423494B2 (en) | Method for producing 2-hydroxycarboxylic acid | |
| JP5205971B2 (en) | Method for producing tetrahydropyran compound | |
| JP4030289B2 (en) | Process for producing β-ketonitriles | |
| US5258521A (en) | Process of producing optically active propionic acid ester derivatives | |
| JP3823385B2 (en) | Process for producing 2,4,5-trifluoro-3-iodobenzoic acid and esters thereof | |
| CN107827811B (en) | Method for preparing N-substituted-1, 2,3, 6-tetrahydropyridine | |
| JP2004238322A (en) | Method for producing (r)-3-aminopentanenitrile methanesulfonic acid salt | |
| CN104910078B (en) | Preparation method for rosuvastatin calcium intermediate | |
| JP4165110B2 (en) | Preparation of 4-oxypyrimidine derivatives | |
| CN113527137A (en) | Preparation method of characteristic impurities of trifloxystrobin | |
| JP2023532363A (en) | Method for producing isoxazoline-containing uracil-based compound intermediate | |
| CN114805065A (en) | Preparation method of oxalyl chloride monoester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |